- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06867107
SAT-3247-CL-101 연구를 완료 한 참가자를위한 장기 후속 연구
SAT-3247-CL-101에 참여한 Duchenne 근이영양증 (DMD) 환자에서 SAT-3247의 오픈 라벨 장기 추적 연구 연구
This is an open-label long-term safety and efficacy study of orally administered SAT-3247 in patients with DMD including those who previously participated in SAT-3247-CL-101.
The study will assess the long-term safety, tolerability and potential efficacy of long-term dosing of orally administered SAT-3247 60 mg in a 5-days on/2-days off (i.e. weekday dosing) regimen in an open-label design through 11 months (Group A) or 12 months (Group B), respectively. The study will enroll up to 30 participants, including up to 5 who previously participated in the SAT-3247-CL-101 study.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90095
- University of California, Los Angeles
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
-
Ohio
-
Columbus, Ohio, 미국, 43205
- Nationwide Children's Hospital
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38105
- St. Jude Children's Research Hospital
-
-
-
-
Victoria
-
Melbourne, Victoria, 호주, 3052
- The Royal Children's Hospital
-
Melbourne, Victoria, 호주
- St. Vincent Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Previously participated in the SAT-3247-CL-101 parent clinical trials (Group A only).
- No previous treatment with SAT-3247 (Group B only)
- Continued status of stable glucocorticosteroid dose or no glucocorticosteroid dose for the duration of the trial.
- Continued stable doses of prescription medicines (excluding glucocorticosteroids) and over-the-counter medicines and/or herbal supplements for supportive care for the duration of the trial.
- Previously received delandistrogene moxeparvovec (brand name Elevidys) either in a prior clinical trial or in the commercial setting > 18 months prior to screening whose muscle function tests have stabilized or demonstrated decline ≥ 3 months prior to Screening (Group B only)
- Receiving a stable dose of givinostat (brand name Duvyzat) for at least 18 months or longer prior to the Screening (Group B only)
- Have previously received an exon skipper ≥ 6 months prior to Screening whose muscle function tests have stabilized or demonstrated decline ≥ 3 months prior to Screening (Group B only)
- Have received any medication indicated for DMD (other than corticosteroids, including vamorolone, gene therapy, givinostat, or an exon-skipping therapy) whose last dose was ≥ 6 months prior to Screening (Group B only)
- have received prior treatment with an investigational gene therapy product (other than delandistrogene moxeparvovec) ≥ 24 months prior to Screening
- Ejection fraction ≥ 40% at Screening (Group B only)
- Ability to understand the nature of the trial and any hazards of participating.
- Ability to communicate satisfactorily with the investigator and physiotherapist and to participate in and comply with the requirements of the entire trial including scheduled visits, procedures, laboratory tests, questionnaires, wearable devices, and study restrictions.
- Willingness to give written consent or assent (if not of cognitive capacity of consent in the jurisdiction where the study is being conducted) and parent/legal guardian willing to give written consent to participate (if participant is not of cognitive capacity to consent) after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate.
- All participants, if sexually active, agree to follow the contraception requirements and sperm donation limitations of the trial as described in the protocol.
Exclusion Criteria:
-
Presence of acute medical condition, chronic illness or history of chronic illness (other than DMD) sufficient to invalidate the participant's participation in the trial or make it unnecessarily hazardous in the judgment of the investigator.
-
Evidence of significant hepatic dysfunction, defined as GLDH > 2X upper limit of normal (ULN) at Screening (Group B only)
-
Entry item score on the Performance of Upper Limb (PUL2.0) assessment > 5 (Group B only)
-
Requirement for daytime ventilator assistance (Group B only)
-
Participants expected to require spine surgeries or hospitalizations for non-acute health needs within 12 months.
-
Participants with acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) or acute infection (such as influenza) or a significant infection or known inflammatory process at Screening.
-
Severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator.
-
Development of symptomatic cardiomyopathy since completion of the parent trial.
-
Inability to swallow tablets.
a. Tablets can be split or crushed and stirred into flavored beverages or food (e.g., apple sauce, yogurt) followed by immediate administration.
-
Receipt of an investigational product (including prescription medicines and investigational devices) as part of another clinical trial since completion of the parent trial or in the follow-up period of another clinical trial at the time of Screening for this study.
a. Use of deflazacort or vamorolone in jurisdictions where these are considered investigational as they have not received health authority marketing authorization will not be exclusionary.
-
Current or expected use during the study of any medications that are known strong or moderate inhibitors of CYP3A4 (Group B only)
-
Consumption of grapefruit, grapefruit juice, and grapefruit-containing products within 30 days of the first dose of investigational product and for the duration of the study (Group B only)
-
Possibility that the participant will not cooperate with the requirements of the protocol or is unable or unwilling to comply with the study requirements according to investigator's decision.
-
Employee, contractors, or consultants of the Sponsor, the CRO, and/or study site or their relatives.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Treatment Arm
SAT-3247 60 mg administered orally in a 5-days on/2-days off (weekday) dosing regimen |
AAK1 inhibitor |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment emergent adverse events
기간: 12 months
|
Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) |
12 months
|
|
SAT-3247 effect on fat fraction in biceps brachii
기간: 12 months
|
Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. |
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
SAT-3247 effects on muscle force
기간: 12 months
|
Changes from baseline in muscle force measurements as determined by dynamometry following treatment. |
12 months
|
|
Potential for improvement in muscle function with treatment of SAT-3247
기간: 12 months
|
Changes from baseline in Performance of Upper Limb (PUL2.0) assessment following SAT-3247 treatment. |
12 months
|
|
PK measurement of SAT-3247
기간: 12 months
|
Evaluate PK of SAT-3247 concentrations in non-ambulatory participants |
12 months
|
|
Long-term effects of SAT-3247 on muscle quantitative magnetic resonance (qMR)
기간: 12 months
|
Evaluate change in proton muscle transverse relaxation time (T2) in biceps brachii |
12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SAT-3247-LT-001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .